195 related articles for article (PubMed ID: 23505231)
1. Kinetics of the long-term antibody response after meningococcal C vaccination in patients with juvenile idiopathic arthritis: a retrospective cohort study.
Stoof SP; Heijstek MW; Sijssens KM; van der Klis F; Sanders EA; Teunis PF; Wulffraat NM; Berbers GA
Ann Rheum Dis; 2014 Apr; 73(4):728-34. PubMed ID: 23505231
[TBL] [Abstract][Full Text] [Related]
2. Safety and efficacy of meningococcal c vaccination in juvenile idiopathic arthritis.
Zonneveld-Huijssoon E; Ronaghy A; Van Rossum MA; Rijkers GT; van der Klis FR; Sanders EA; Vermeer-De Bondt PE; Hoes AW; van der Net JJ; Engels C; Kuis W; Prakken BJ; Van Tol MJ; Wulffraat NM
Arthritis Rheum; 2007 Feb; 56(2):639-46. PubMed ID: 17265499
[TBL] [Abstract][Full Text] [Related]
3. Antibody persistence in Australian adolescents following meningococcal C conjugate vaccination.
Perrett KP; Richmond PC; Borrow R; Nolan T; McVernon J
Pediatr Infect Dis J; 2015 Mar; 34(3):279-85. PubMed ID: 25742078
[TBL] [Abstract][Full Text] [Related]
4. Salivary antibody levels in adolescents in response to a meningococcal serogroup C conjugate booster vaccination nine years after priming: systemically induced local immunity and saliva as potential surveillance tool.
Stoof SP; van der Klis FR; van Rooijen DM; Bogaert D; Trzciński K; Sanders EA; Berbers GA
Vaccine; 2015 Jul; 33(32):3933-9. PubMed ID: 26100925
[TBL] [Abstract][Full Text] [Related]
5. Antibody persistence after serogroup C meningococcal conjugate immunization of United Kingdom primary-school children in 1999-2000 and response to a booster: a phase 4 clinical trial.
Perrett KP; Winter AP; Kibwana E; Jin C; John TM; Yu LM; Borrow R; Curtis N; Pollard AJ
Clin Infect Dis; 2010 Jun; 50(12):1601-10. PubMed ID: 20459323
[TBL] [Abstract][Full Text] [Related]
6. Long-term persistence of protective antibodies in Dutch adolescents following a meningococcal serogroup C tetanus booster vaccination.
van Ravenhorst MB; Marinovic AB; van der Klis FR; van Rooijen DM; van Maurik M; Stoof SP; Sanders EA; Berbers GA
Vaccine; 2016 Dec; 34(50):6309-6315. PubMed ID: 27817957
[TBL] [Abstract][Full Text] [Related]
7. Induction of salivary antibody levels in Dutch adolescents after immunization with monovalent meningococcal serogroup C or quadrivalent meningococcal serogroup A, C, W and Y conjugate vaccine.
van Ravenhorst MB; den Hartog G; van der Klis FRM; van Rooijen DM; Sanders EAM; Berbers GAM
PLoS One; 2018; 13(4):e0191261. PubMed ID: 29672552
[TBL] [Abstract][Full Text] [Related]
8. Immunity against Neisseria meningitidis serogroup C in the Dutch population before and after introduction of the meningococcal c conjugate vaccine.
de Voer RM; Mollema L; Schepp RM; de Greeff SC; van Gageldonk PG; de Melker HE; Sanders EA; Berbers GA; van der Klis FR
PLoS One; 2010 Aug; 5(8):e12144. PubMed ID: 20730091
[TBL] [Abstract][Full Text] [Related]
9. Five-year antibody persistence and safety following a booster dose of combined Haemophilus influenzae type b-Neisseria meningitidis serogroup C-tetanus toxoid conjugate vaccine.
Tejedor JC; Merino JM; Moro M; Navarro ML; Espín J; Omeñaca F; García-Sicilia J; Moreno-Pérez D; Ruiz-Contreras J; Centeno F; Barrio F; Cabanillas L; Muro M; Esporrin C; De Torres MJ; Caubet M; Boutriau D; Miller JM; Mesaros N
Pediatr Infect Dis J; 2012 Oct; 31(10):1074-7. PubMed ID: 22828645
[TBL] [Abstract][Full Text] [Related]
10. Use of saliva to monitor meningococcal vaccine responses: proposing a threshold in saliva as surrogate of protection.
van Ravenhorst MB; van der Klis FRM; van Rooijen DM; Sanders EAM; Berbers GAM
BMC Med Res Methodol; 2019 Jan; 19(1):1. PubMed ID: 30611213
[TBL] [Abstract][Full Text] [Related]
11. Kinetics of Meningococcal Serogroup C-Specific Functional Antibody Levels Up to 15 Years after a Single Immunization with a Meningococcal Serogroup C Conjugate Vaccine during Adolescence.
Stoof SP; van Ravenhorst MB; van Rooijen DM; de Voer RM; van der Klis FRM; Boland GJ; Sanders EAM; Berbers GAM; Teunis PF
Clin Vaccine Immunol; 2017 Feb; 24(2):. PubMed ID: 27881489
[TBL] [Abstract][Full Text] [Related]
12. Investigation of serum bactericidal activity in childhood and adolescence 3-6 years after vaccination with a single dose of serogroup C meningococcal conjugate vaccine.
Sakou II; Tzanakaki G; Tsolia MN; Sioumala M; Barbouni A; Kyprianou M; Papaevangelou V; Tsitsika A; Blackwell CC; Kafetzis D; Kremastinou J
Vaccine; 2009 Jul; 27(33):4408-11. PubMed ID: 19500554
[TBL] [Abstract][Full Text] [Related]
13. Kinetics of antibody responses after primary immunization with meningococcal serogroup C conjugate vaccine or secondary immunization with either conjugate or polysaccharide vaccine in adults.
de Voer RM; van der Klis FR; Engels CW; Schepp RM; van de Kassteele J; Sanders EA; Rijkers GT; Berbers GA
Vaccine; 2009 Nov; 27(50):6974-82. PubMed ID: 19800445
[TBL] [Abstract][Full Text] [Related]
14. Influence of prior meningococcal C polysaccharide vaccination on the response and generation of memory after meningococcal C conjugate vaccination in young children.
Borrow R; Goldblatt D; Andrews N; Richmond P; Southern J; Miller E
J Infect Dis; 2001 Aug; 184(3):377-80. PubMed ID: 11443568
[TBL] [Abstract][Full Text] [Related]
15. B cell memory to a serogroup C meningococcal conjugate vaccine in childhood and response to booster: little association with serum IgG antibody.
Perrett KP; Jin C; Clutterbuck E; John TM; Winter AP; Kibwana E; Yu LM; Curtis N; Pollard AJ
J Immunol; 2012 Sep; 189(5):2673-81. PubMed ID: 22855707
[TBL] [Abstract][Full Text] [Related]
16. Serologic responses to ACYW135 polysaccharide meningococcal vaccine in Saudi children under 5 years of age.
Al-Mazrou Y; Khalil M; Borrow R; Balmer P; Bramwell J; Lal G; Andrews N; Al-Jeffri M
Infect Immun; 2005 May; 73(5):2932-9. PubMed ID: 15845499
[TBL] [Abstract][Full Text] [Related]
17. Long-term seroprotection after an adolescent booster meningococcal serogroup C vaccination.
de Whalley PC; Snape MD; Plested E; Thompson B; Nuthall E; Omar O; Borrow R; Pollard AJ
Arch Dis Child; 2013 Sep; 98(9):686-91. PubMed ID: 23853000
[TBL] [Abstract][Full Text] [Related]
18. Population-Level Persistence of Immunity 2 Years After the PsA-TT Mass-Vaccination Campaign in Mali.
Basta NE; Borrow R; Berthe A; Dembélé AT; Onwuchekwa U; Townsend K; Boukary RM; Mabey L; Findlow H; Bai X; Sow SO
Clin Infect Dis; 2015 Nov; 61 Suppl 5(Suppl 5):S547-53. PubMed ID: 26553687
[TBL] [Abstract][Full Text] [Related]
19. Different Dynamics for IgG and IgA Memory B Cells in Adolescents following a Meningococcal Serogroup C Tetanus Toxoid Conjugate Booster Vaccination Nine Years after Priming: A Role for Priming Age?
Stoof SP; Buisman AM; van Rooijen DM; Boonacker R; van der Klis FR; Sanders EA; Berbers GA
PLoS One; 2015; 10(10):e0138665. PubMed ID: 26458006
[TBL] [Abstract][Full Text] [Related]
20. Seroprevalence of antibodies against serogroup C meningococci in England in the postvaccination era.
Trotter CL; Borrow R; Findlow J; Holland A; Frankland S; Andrews NJ; Miller E
Clin Vaccine Immunol; 2008 Nov; 15(11):1694-8. PubMed ID: 18827191
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
